Making Early Disease Detection Possible
Discover how VeraBIND is redefining diagnostics.
At Veravas, our diagnostic technology brings greater clarity to complex diseases. Our patented VeraBIND™ platform addresses long-standing challenges in laboratory testing by reducing interference and making it possible to measure hard-to-detect biomarkers, supporting deeper insight into disease biology, including Alzheimer’s and other dementias.
VeraBIND TauInnovative Blood Test for Alzheimer's Early Detection
Our latest application for VeraBIND™ is in the early detection of tau pathology associated with Alzheimer’s disease (AD). The tau protein is one of the hallmark proteins of AD and early detection of such biomarkers is a crucial area of research.1
VeraBIND:Advanced Research Solutions for Early Disease Detection
VeraBIND tests and pre-treatment solutions provide breakthrough capabilities in detecting and analyzing biomarkers of interest, with a focus on enhanced assay sensitivity and reliable detection. Our innovative technology enhances sample preparation, and provides accurate, and reproducible results across a wide range of diseases.
Regardless of sample type or biomarker of interest, VeraBIND technology offers the reliability and accuracy needed to accelerate research to make impactful discoveries, perform liquid biopsies, or improve test accuracy.
- Thal DR, Tomé SO. The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204-217. doi:10.1016/j.brainresbull.2022.10.006 https://pubmed.ncbi.nlm.nih.gov/36244581/